All In Biotech

Drug Trial Radar · NCT07479641

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Apr 14, 2026

Primary completion

Sep 14, 2026

Study completion Sep 14, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.

Conditions

  • Cardiomyopathy

Interventions

  • Test formulation of HRS-1893 tabletDrug

    Test formulation of HRS-1893 tablet, oral.

  • Reference formulation of HRS-1893 tabletDrug

    Reference formulation of HRS-1893 tablet, oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak concentration (Cmax).Time frame: From Day 1 to Day 17.
  2. Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t).Time frame: From Day 1 to Day 17.
  3. Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞).Time frame: From Day 1 to Day 17.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.